Abstract-Ultrasound (US) is believed to be a novel and effective tool to locally deliver gene into target tumors. US can temporally change the permeability of cell membrane and thus enhance the delivery of naked DNA into cells. In this study, the gene transfection in tumor and muscle tissues was evaluated by changing the contrast agent concentrations and US exposure durations. The luciferase and IL-12 mixed with SonoVue ® were injected intramuscularly (IM) or intratumorally (IT), followed by exposure to US of 20% in duty cycle and 2 W/cm 2 in intensity. The serum levels of IL-12 were determined by ELISA. Experimental results showed that both local and systemic expressions of the naked DNA in muscle are significantly higher than those in subcutaneous and liver tumors, and an order of muscle > subcutaneous tissue > liver tumor was found. Best transfection efficiency could be obtained by using 50% SonoVue in tumor and 30% in muscle after 10 min US exposure.
INTRODUCTION
Hepatoccelular carcinoma (HCC) is the fifth most common tumor worldwide, and it is also one of the first leading cancers in Taiwan. According to the statistic results, one-third of the estimated 350,000 new case per year occur in China and another third elsewhere in Asia. In Asia, the infection of Hepatitis B and C viruses was the major causation of HCC 1 . Cancer gene therapy is promptly advancing due to its attractiveness of high sensitivity and specificity, and it creates new potentiality for the treatment of HCC 2 . Many studies have shown that viral vectors as a gene carrier can result in more efficient transfection comparing with naked plasmid DNA 3, 4 . However, the critical concerns about possible adverse side effects, such as immune response to viruses and insertional mutagenesis, have arisen, especially for the use of viruses as vectors when clinical trials are involved 4 .
In contrast, nonviral methods, lacking the above problems, may have unique advantages for clinical applications. Various non-viral methods for gene delivery have been proposed, e.g., naked gene injection or combining with electroporation technique 5 . Although the combination of gene transfer with electroporation in vivo is effective, the tissue damage due to the electric pulse is debatable. On the other hand, recent reports have shown that US can induce cell-membrane porosity to enhance the delivery of naked DNA into cells in vitro 6 . Via these pores, naked DNA suspended in the medium can leak into cells and remain trapped into cytoplasm 8 . However, the cell-membrane porosity reduced quickly after removing the US exposure, which retained the survival of cells 6 . The phenomenon of cell-membrane porosity and resealing induced by US was defined as sonoporation 7 . Recent studies demonstrated that a combination of US with ultrasound contrast agents (UCA) can improve the permeability of naked plasmid DNA into tumors in vivo 8 . Cavitation, the activation of small dissolved gas nuclei in the presence of an acoustic pressure field, is believed to be responsible for the "temporal holes" on cell membranes.
In vivo sonoporation has been used successfully for efficient delivery of plasmid DNA into many different tissue such as skeletal muscle, kidneys, heart and hepatocellular carcinoma 8, 9 . Local expression of a gene or cDNA encoded by a plasmid in tumor tissue can be achieved by locally exposing to pulsed high-intensity focused US in tumors 10 . Systemic gene expression has also been demonstrated, which implied that a safe and efficient non-viral gene transfer method may be used. After transfection, the transgene products such as human growth factor or IL-12 protein may be secreted from skeletal muscular fibers to target tumors or tissue by blood vessels. Skeletal muscle has numerous advantages for sonoporation, for example, large mass (30% of the adult body mass) for gene delivery approaches, abundant blood vascular supply for the carriage of secreted protein into the circulation, and the dispersal of transgene by the syncytial nature of muscle fibers. Therefore, muscle itself could be a good candidate for producing transgene proteins and served as systemic therapeutic reagents 11 .
In this study, the gene transfection efficiency in tumors and muscle tissues was evaluated by changing the contrast agent concentrations or ultrasound exposure durations. The luciferase and interleukin-12 (IL-12) mixed with SonoVue ® were injected IM or IT, and US was applied at 20% duty cycle (DC) and 2 W/cm 2 intensity. The expression duration of transgene products was also evaluated and compared in different tissue models.
II. EXPREIMENTAL MATERIALS AND METHODS

A. Subcutaneous tumor model
To optimize gene transfection in vivo, male BALB/c mice (6 weeks old, 18-20 g) were inoculated subcutaneously (SC) into the flank with 5×10 5 BNL cells per mouse. Seven days later, when tumors reached the size of 100mm 3 , animals were randomly divided into groups of five mice each.
B. Generation of orthotopic liver tumor
After anesthesia, the abdominal cavities of the mice were opened to expose the liver lobe using forceps. BNL cell line (3 × 10 5 /mouse) was injected into the liver using syringe (Terumo, Elkton, MD). The needle hole was sealed with an electric coagulator (Aaron, Petersburg, FL) immediately after withdrawing needles to avoid leakage of the injected substance. The incision was subsequently sutured. The animals were randomized for further treatment.
C. Experimental Procedures
To understand the effect of tissue type and host environment on ultrasound-mediated gene transfection, and also the optimal contrast agent concentration and exposure duration, 100 μ g of cDNA coding for both luciferase and IL-12, mixing with SonoVue ® contrast agent, were injected into mice IM or IT (including orthotopic liver tumor and subcutaneous (SC) tumor models). The effect of SonoVue ® concentration on transfection efficiency was first examined. SonoVue ® was added to the medium at various concentrations (0, 10, 30 or 50%), and ultrasound irradiation was applied for 20 min at 20% DC and 2 W/cm 2 in intensity. The effect of ultrasound exposure duration on transfection efficiency was examined next. The luciferase reporter gene (100μg) was injected into three various type of tissues, followed by various durations of ultrasound exposure (0, 5, 10, 20 or 30 min). The tested tissues were harvested on Day 4 for luciferase assay.
Tissue blocks from muscle, orthotopic liver tumor and SC tumor models were all collected for luciferase quantitative assays. Each collected sample was homogenized in 100 μ l luciferase lysis buffer (CCLR, Promega), and the solution was centrifuged. After determining protein concentrations, 20 μ l supernatant (10 μ g of total protein) was analyzed in a luminometer (Plate Chameleon V Microplate Reader, Hidex Oy, Turku, Finland) using a commercial substrate (Luciferase Assay System, Promega). Then, relative luminescence intensity per mg protein (RLU/mg) was determined.
To determine the expression duration of transfected plasmid in vivo, animals were assigned randomly into 3 groups, including an orthotopic liver tumor group, a SC tumor group and a muscle group. In this experiment, the expression of IL-12 DNA was measured by enzyme-linked immunosorbent assay (ELISA) at 3, 6, 9 or 12 day post-US application. For detection of IL-12 in serum, blood sample was collected by orbital puncture at room temperature. Serum was extracted from blood samples by centrifugation (10 minutes at 5000 rpm) at 4 ℃ , and stored at -20 ℃ until analysis. Serum samples were analyzed using mouse IL-12 ELISA kits (BD OpEIA TM , BD Pharmingen, San Diego, CA, USA) and displayed as pg of IL-12 per ml of serum.
III. RESULTS
A. Optimization of in vivo Transfection
For SonoVue ® at various concentrations (0, 10, 30 or 50%), the gene transfection efficiency increased in a dose-dependent manner with the concentration of SonoVue ® addition, but there was no significant difference in transfection efficiency between 30% and 50% SonoVue ® (Fig. 1) . For exposure duration, 5 min US exposure induced significant gene expression in all tissue types as shown in Fig. 2 . However, the efficacy of ultrasound exposure didn't differ significantly among 5, 10, 20 and 30 min. Therefore, the concentration of added SonoVue ® was a more important parameter for gene transfection in our study. For future experiments, irradiation duration of 10 min was used.
B. The Duration of IL12 Expression in vivo
Serum level of IL-12 was highest after IM injection followed by sonoporation (Fig. 3) , and IL-12 increased with time and had the highest peak at 237 pg/ml on day 6 after treatment. However, serum level of IL-12 decreased thereafter. Serum level of IL-12 from mice treated with IM and IT injection (for SC tumor) and US exposure was significantly higher than that in mice that received no treatment (P < 0.05). However, serum level of IL-12 in mice treated with IT injection (for orthotopic liver tumor) followed by sonoporation failed to show significant results (P > 0.05).
IV. DISCUSSION
In this study, the optimal contrast agent concentration and US exposure duration for gene transfection in tumor and muscle tissues were studied. The luciferase and IL-12 mixed with SonoVue ® were injected IM and IT, and US was applied at 20% DC and 2 W/cm 2 . The gene transfection could be enhanced by 50% SonoVue ® in tumor and 30% in muscle after 10 min US exposure. Probably because muscle tissue could uptake luciferase automatically and the injury to muscle cells by microbubbles was small, the luciferase gene expression in muscle was higher than that in tumor tissue. Our results also showed that the prolongation of exposure duration could not effectively increase the gene expression in tissues. Moreover, Because of the degradation of IL-12 transgene products, serum levels of IL-12 had the highest expression at 6 days post-US exposure.
US can induce cell-membrane porosity and enhance the delivery of naked DNA into cells in vitro. To obtain the best transfection efficiency, the differences in luciferase gene expression in various tissues was evaluated by changing the SonoVue ® concentration and the duration of US exposure in vivo. When different tissues were treated with US of fixed total power, luciferase gene expression efficiency was found to increase with the SonoVue ® concentration (Fig. 1) . Large SonoVue ® addition might induce great quantity of pores on cell membrane, and this resulted more luciferase gene to diffuse into cells and high gene expression efficiency. Comparing with tumor tissues, the quantity of luciferase gene expression in muscle tissue was the highest. Which may partially due to the auto-uptake of DNA into muscle cells when DNA was injected. Because of the auto-uptake and long-term expression of DNA following simple intramuscular injection, intramuscular gene delivery has also been employed in clinical trials of DNA vaccination.
Some previous studies show that US exposure duration is a key factor for gene transfection efficiency, and the longer exposure duration results in higher gene expression. Therefore, the transfection efficiency for different US exposure duration was evaluated in our study. Figure 2 showed the gene transfection efficiency of three tested tissues treated with different duration of US. It was found that prolonging the US exposure duration could not enhance the gene transfection effectively. Although no explanation about the exposure duration to gene tansfection in vivo has been given, this result might be due to the disappearance of the SonoVue ® after 5-10 min post-injection, and cavitation could no longer be sustained in these three tested tissues to facilitate the transgene diffusion into targeting cells Figure 3 showed the results of IL-12 expression in various tissues 3, 6, 9 or 12 day post-US exposure. Because of the degradation of IL-12 transgene products, serum levels of IL-12 peaked at the 6 th day post-US exposure, and reduced gradually thereafter.
In summary, the present study showed that large gene transfection could be generated in muscle tissue by optimal SonoVue ® concentration and US exposure duration. Muscle seems to be a good candidate for producing large amount of gene product. In the future, muscle might be able to serve as a host for certain antitumor gene, such as an angiogenesis inhibitor gene, and a effective factory for manufacturing its protein product, which was then secreted into bloodstream and transported to the target site to exert its therapeutic function. 
